These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines. Pezzino S; Luca T; Castorina M; Puleo S; Latteri S; Castorina S Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38255708 [TBL] [Abstract][Full Text] [Related]
6. Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study. Kouvari M; Valenzuela-Vallejo L; Axarloglou E; Verrastro O; Papatheodoridis G; Mingrone G; George J; Mantzoros CS Liver Int; 2024 Mar; 44(3):848-864. PubMed ID: 38263703 [TBL] [Abstract][Full Text] [Related]
7. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018. Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights. Aggeletopoulou I; Tsounis EP; Triantos C Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118 [TBL] [Abstract][Full Text] [Related]
9. Roles of immune dysregulation in MASLD. Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736 [TBL] [Abstract][Full Text] [Related]
12. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Armandi A; Bugianesi E Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842 [TBL] [Abstract][Full Text] [Related]
13. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759 [TBL] [Abstract][Full Text] [Related]
14. The pathophysiology of MASLD: an immunometabolic perspective. Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354 [TBL] [Abstract][Full Text] [Related]
15. Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Ramanathan R; Patwa SA; Ali AH; Ibdah JA Cells; 2023 Dec; 12(24):. PubMed ID: 38132126 [TBL] [Abstract][Full Text] [Related]
16. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Zhao S; Guo Y; Yin X Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834 [TBL] [Abstract][Full Text] [Related]
17. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290 [TBL] [Abstract][Full Text] [Related]
18. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease. Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586 [TBL] [Abstract][Full Text] [Related]
19. Innate Immunity and MASLD. Meyer M; Schwärzler J; Jukic A; Tilg H Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672492 [TBL] [Abstract][Full Text] [Related]
20. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease. Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]